| |
Early remission
|
Arm 1
|
Arm 2
| |
OP group
|
|---|
|
Patient characteristics at follow-up visits
|
(N = 387)
|
(N = 83)
|
(N = 78)
|
P
|
(N = 50)
|
|---|
|
4 months
| | | | | |
|
DAS
|
0.97 (0.40)
|
2.49 (0.63)
|
2.57 (0.68)
|
0.47
|
2.31 (0.63)
|
|
HAQ
|
0.23 (0.33)
|
0.86 (0.57)
|
0.88 (0.57)
|
0.77
|
0.73 (0.68)
|
|
MACTAR
|
58.2 (15.7)
|
52.8 (15.1)
|
48.9 (18.8)
|
0.14
|
51.6 (14.1)
|
|
MCS
|
52.4 (8.0)
|
48.8 (9.9)
|
50.7 (10.8)
|
0.26
|
49.8 (10.5)
|
|
PCS
|
51.7 (8.1)
|
39.4 (9.7)
|
38.1 (9.4)
|
0.44
|
42.5 (9.4)
|
|
VASgl, mm
|
14 (14)
|
37 (21)
|
39 (21)
|
0.61
|
28 (22)
|
|
VASda, mm
|
12 (15)
|
42 (24)
|
43 (24)
|
0.74
|
32 (25)
|
|
VASpain, mm
|
10 (14)
|
39 (24)
|
38 (24)
|
0.79
|
27 (24)
|
|
VASms, mm
|
11 (17)
|
40 (27)
|
39 (27)
|
0.78
|
32 (30)
|
|
8 months
| | | | | |
|
DAS
|
1.29 (0.69)
|
1.97 (0.87)
|
2.01 (0.91)
|
0.77
|
2.02 (0.84)
|
|
HAQ
|
0.35 (0.44)
|
0.74 (0.61)
|
0.81 (0.64)
|
0.51
|
0.68 (0.59)
|
|
MACTAR
|
56.4 (15.7)
|
55.8 (14.7)
|
54.5 (16.1)
|
0.60
|
48.9 (19.9)
|
|
MCS
|
52.9 (8.4)
|
46.6 (17.9)
|
48.7 (10.3)
|
0.85
|
48.5 (13.0)
|
|
PCS
|
48.9 (9.1)
|
42.8 (10.9)
|
42.5 (11.0)
|
0.26
|
43.7 (9.5)
|
|
VASgl, mm
|
20 (20)
|
33 (23)
|
34 (21)
|
0.75
|
30 (23)
|
|
VASda, mm
|
22 (23)
|
39 (26)
|
33 (24)
|
0.20
|
35 (25)
|
|
VASpain, mm
|
19 (23)
|
35 (26)
|
31 (25)
|
0.36
|
32 (24)
|
|
VASms, mm
|
24 (26)
|
34 (29)
|
37 (28)
|
0.51
|
40 (27)
|
|
1 year
| | | | | |
|
DAS
|
1.31 (0.78)
|
2.07 (0.89)
|
1.77 (0.90)
|
0.04
|
2.20 (0.83)
|
|
HAQ
|
0.38 (0.49)
|
0.87 (0.66)
|
0.81 (0.66)
|
0.60
|
0.77 (0.65)
|
|
MACTAR
|
63.0 (9.4)
|
59.2 (10.3)
|
60.4 (11.9)
|
0.54
|
59.7 (11.21)
|
|
MCS
|
53.1 (8.6)
|
50.5 (10.3)
|
50.5 (10.1)
|
0.97
|
50.4 (11.9)
|
|
PCS
|
48.6 (9.8)
|
39.9 (10.3)
|
43.0 (11.4)
|
0.10
|
42.6 (10.9)
|
|
VASgl, mm
|
20 (21)
|
33 (23)
|
27 (20)
|
0.10
|
33 (24)
|
|
VASda, mm
|
24 (26)
|
42 (29)
|
31 (26)
|
0.02
|
34 (27)
|
|
VASpain, mm
|
21 (23)
|
38 (28)
|
28 (25)
|
0.02
|
28 (25)
|
|
VASms, mm
|
25 (26)
|
41 (31)
|
33 (27)
|
0.96
|
39 (30)
|
|
Remission (DAS <1.6)
|
263 (68)
|
21 (25)
|
32 (41)
|
0.01
|
11 (22)
|
- aData are means ± SD, medians (IQR) or numbers (%) as appropriate. ACPA: anticitrullinated protein antibody; DAS: Disease Activity Score; HAQ: Health Assessment Questionnaire; MACTAR: McMaster Toronto Arthritis Patient Preference Questionnaire; MCS: Mental Component Score on the 36-Item Short Form Health Survey; PSC: Physical Component Score on the 36-Item Short Form Health Survey; RA2010: rheumatoid arthritis according to the 2010 American College of Rheumatology and European League against Rheumatism classification criteria; VASda: disease activity; VASgl: global health; VASms: morning stiffness; VASpain: pain. P-value represents the difference in mean scores and remission rates between arms 1 and 2.
